Latin America: Towards Medicine Sovereignty
When it comes to pharmaceutical exports, Latin America has historically been confined to the margins of the global life science industry. In 2023, the region accounted for a mere one…
Address: Praia de Botafogo 501 1° Andar Bloco Corcovado 22250-040 Rio de Janeiro – RJ,Brazil
Tel: 55 21 3266 6200
Web: http://www1.actelion.com.br/br/index.page
In 2002, Actelion opened its first office in Latin America. Brazil was chosen as the venue due to different factors. The country is a medical centre in the region and is endowed with considerable structure, hospital and medical science. Brazil also possesses a strong political and social framework and is projected to be an important partner in international decisions, not only due its specific significance, such as increasing the performance of its economy.
In addition, it has development programs and conducts scientific and technological research.
Due to its growth potential in pharmaceuticals and its status as one of the largest research centers of reference in the continent, Brazil was chosen to as base of operations for Actelion in Latin America.
Tracleer, Zavesca
When it comes to pharmaceutical exports, Latin America has historically been confined to the margins of the global life science industry. In 2023, the region accounted for a mere one…
Dirk van Niekerk, President and CEO of Boehringer Ingelheim South America, identifies Latin America as a pivotal growth engine. Focusing on cardio, renal, metabolic and oncology pillars, the firm is…
Fernando Almeida, EVP China & International Markets, discusses his global pharma career and Chiesi’s evolution into a high-performing, innovation-led group. He highlights strong double-digit growth, disciplined investment, and expansion across…
From cancer treatments to cardiovascular drugs, access to innovative medicines in South America lags behind developed market norms with patients forced to endure considerable delays for therapies that are already…
Latin America faces one of the most complex healthcare landscapes in the world, where fast-growing demand collides with deep structural inequities and limited resources. In this interview, Fabrizio Signorin, President…
Marco Billi, International CEO of Eurofarma, shares his perspective on the company’s evolution from a Brazilian CMO (Contract Manufacturing Organisation) into one of Latin America’s most internationally active pharmaceutical groups.…
Latin America’s largest and most dynamic pharma market is booming. Despite sluggish macroeconomic growth, agile local firms are consolidating their positions to serve Brazilian patients, while a spate of technology…
Danielle Bibas leads Pierre Fabre’s operations in Brazil, overseeing three key dermo-cosmetic brands – Avène, Darrow, and Ducray – in the world’s third-largest beauty market. Since assuming the role in…
Rare diseases have long fallen through the cracks of Latin America’s health systems, but few figures have done more to change that reality than Toni Daher. What started as a…
Brazil’s push to modernise its health system has put Interfarma at the centre of the region’s biggest access debate. Since taking over the presidency in 2023, Renato Porto has steered…
Alexandre Gibim, senior Vice President of Latin America at AstraZeneca, brings extensive global pharmaceutical leadership experience spanning China, the US, and Canada. In this exclusive interview, he articulates AstraZeneca’s strategic…
Haig Yeghiaian, General Manager at LEO Pharma Brazil, brings extensive therapeutic area expertise spanning HIV, nephrology, and dermatology to his leadership of the company’s multifaceted Brazilian operations. Under his stewardship,…
See our Cookie Privacy Policy Here
